Outcomes among more than 1,800 people newly diagnosed with cardiac sarcoidosis differed by diagnostic features, including heart tissue sampling…
Articles by Steve Bryson, PhD
A study examining patients’ blood and lymph nodes at the time of…
Ear, nose, and throat (ENT) conditions may be underdiagnosed among adults with sarcoidosis, a large U.S. database study suggests.
Atyr Pharma will meet with the U.S. Food and Drug Administration (FDA) next month to review results from the Phase…
The Foundation for Sarcoidosis Research (FSR) has announced $400,000 in new funding to support early-stage research projects aimed at…
The Foundation for Sarcoidosis Research (FSR) brought together more than 40 leading clinicians and researchers from around the world…
Higher, daily exposure to microorganisms during childhood is significantly associated with an increased chance of developing sarcoidosis in adulthood,…
Atyr Pharma and the U.S. Food and Drug Administration (FDA) have aligned on the specific main outcome analysis of…
A global Phase 3 clinical trial evaluating efzofitimod, Atyr Pharma’s investigational therapy, in people with pulmonary sarcoidosis will…
Damage to and the loss of bile ducts, which are the tubes that carry the digestive fluid bile from the…